Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM383 Single Dose Escalation in Healthy Males
NCT06412185Phase 1Recruiting
- Sponsor
- Keymed Biosciences
- Start
- May 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CM383 in Alzheimer's disease (AD) (6 arms), sponsored by Keymed Biosciences. Primary endpoint: Incidence of adverse events. Started May 2024; status: recruiting.
02
Drugs
CM383
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06412185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06412185.